Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.620 -0.340 (-6.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 38,145,680
Open 4.980
Bid (Size) 4.630 (200)
Ask (Size) 4.640 (1,500)
Prev. Close 4.960
Today's Range 4.600 - 4.990
52wk Range 3.790 - 12.36
Shares Outstanding 168,425,907
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as... 
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
Recursion Pharmaceuticals (NASDAQ:RXRX) Reports Q3 2025 Results with Revenue Miss and Extended Cash Runway
Recursion's Q3 2025 results show a major revenue miss and widening loss, but the company highlights strong partnerships and a cash runway into 2027. 
Via Chartmill

Performance

YTD
-35.9%
-35.9%
1 Month
-16.5%
-16.5%
3 Month
-15.7%
-15.7%
6 Month
+10.3%
+10.3%
1 Year
-32.3%
-32.3%

More News

Read More
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For November 5, 2025
Via Benzinga
Recursion Pharmaceuticals (RXRX) CEO Sells 100,000 Shares
Via The Motley Fool
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
From Recursion Pharmaceuticals
Via GlobeNewswire
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
Via TokenRing AI
Topics Artificial Intelligence
3 Things Investors Need to Know About Recursion Pharmaceuticals
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
The AI Imperative: Why Rapid Upskilling is Non-Negotiable for Pharma’s Future
Via TokenRing AI
Topics Artificial Intelligence Economy
AI Revolutionizes Pharma R&D: A New Era of Accelerated Drug Discovery and Personalized Medicine
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?
Via The Motley Fool
Topics Artificial Intelligence Economy
AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare
Via TokenRing AI
Topics Animal Testing Artificial Intelligence
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th
From Recursion Pharmaceuticals
Via GlobeNewswire
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks
Via Benzinga
Short Squeeze Frenzy Fuels October's Market Rebound: A Closer Look at Bearish Bets and Bullish Surges
Via MarketMinute
Topics Economy Stocks World Trade
Up 25% in 1 Month, Is This Stock a Buy?
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Artificial Intelligence
3 Growth Stocks to Invest $1,000 in Right Now
Via The Motley Fool
Most active stocks in Thursday's session
Via Chartmill
Is Recursion Pharmaceuticals a Millionaire Maker?
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering
Morgan Stanley, T1 Energy, Bunge Global, Bank of America And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
AI Agents Usher in a New Era of Pharmaceutical Discovery: Accelerating Cures to Market
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
Via MarketMinute
Topics Artificial Intelligence
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk
Via MarketBeat
Topics Artificial Intelligence

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 4.620
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 11/06/25 04:00 PM ET
What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 778.13M
How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Recursion Pharmaceuticals, Inc. - Class A Common Stock has 778M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.